Navigation Links
LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
Date:11/6/2012

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.  The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, lead investigator in the recently completed study.

"The results from this trial demonstrate potential benefits of inhibiting SGLT1 in addition to the known effects of SGLT2 inhibition, not only in improving glycemic control, but also in achieving reductions in important cardiovascular risk factors such as blood pressure and body weight with an apparent favorable safety profile that will need confirmation by long-term controlled trials," said Dr. Rosenstock.  

LX4211, an investigational, oral, dual inhibitor of sodium glucose co-transporters 1 and 2 (SGLT1 and SGLT2), reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. In the trial, LX4211 was tested in 299 patients with poorly controlled type 2 diabetes on metformin therapy. Patients were randomized to receive LX4211 at doses of 75 mg QD, 200 mg QD, 200 mg BID, 400 mg QD, or placebo for 12 weeks. New data presented today showed that maximal 24-hour urinary glucose excretion occurred at 200 mg QD dose, whereas maximal HbA1c reduction was obtained at the 400 mg QD dose. This suggests that dual
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
2. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
3. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
6. Isis Announces Expedited Development Of ISIS-TTR Rx And Amendment To The Collaboration With GSK To Support Phase 2/3 Study
7. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
8. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
9. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
10. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
11. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014  Decision Resources Group finds that ... factor (VEGF) agent for wet AMD, is equally likely ... as Genentech,s Lucentis, which is the standard of care ... organization (MCO) directors do not identify a clear clinical ... likely than Lucentis to be listed on tier 1 ...
(Date:9/18/2014)... -- Zacks.com announces the list of stocks featured in the ... discuss the latest news and events impacting stocks and ... include the Avanir Pharmaceuticals (Nasdaq: AVNR - Free Report ... ), Orexigen (Nasdaq: OREX - Free Report ), ... Gilead (Nasdaq: GILD - Free Report ). ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
Breaking Medicine Technology:Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... elderly men should not be routinely screened for prostate ... new study led by researchers at Henry Ford Hospital., ... JAMA Internal Medicine , focused on the use ... prostate cancer., "We found that the effect of the ... in particular has been minimal at best," says Jesse ...
(Date:9/18/2014)... September 18, 2014 As testosterone ... in U.S. courts, Bernstein Liebhard LLP notes that ... U.S. Food & Drug Administration (FDA) subject prescription ... implemented, could greatly reduce their use. The joint ... Drug Advisory Committee, and the Drug Safety and ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 2Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 3Health News:Testosterone Treatment News: Bernstein Liebhard LLP Notes Experts’ Recommendations for New Restrictions on Low Testosterone Therapy 4
... -- A 2005 voluntary federal ban on the use of ... on all commercial shipping of such purchases within the United ... sell cigarettes, new research reveals. The ban was the ... private shippers, such as UPS and FedEx, made primarily to ...
... Reporter , FRIDAY, Feb. 25 (HealthDay News) -- Medical ... unique ways to solve challenging problems. But scientists can ... diseases, particularly when those methods involve animals or insects. ... team, which is studying fruit flies to help determine ...
... a rare disease and recurrent botulism even more rare. ... drug users has been on the rise and makes ... A new study published in Clinical Infectious ... examines this problem. From 1993 through 2006, 17 ...
... (HealthDay News) -- A fresh look at 19th century Mormon marriage ... offspring any one wife produced. "Although it,s great in terms ... that for every new woman added to a male,s household, the ... study author and evolutionary biologist Michael Wade, from Indiana University in ...
... HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay News) ... to warn of impending dangers to human health if ... They believe the federal government, specifically the Environmental Protection ... emissions, however. "The science is unequivocal that global ...
... the 3rd International Conference on innovative approaches in Head ... colleagues at hospitals and institutes in Denmark presented results ... 7 study. The study, conducted across the country, investigated ... radiotherapy treatment for a head & neck cancer. "We ...
Cached Medicine News:Health News:Study Finds Drop in Online Sales of Cigarettes 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 2Health News:Seeking Alzheimer's Answers Among Fruit Flies 3Health News:19th Century Polygamy Meant Fewer Kids Per Wife, Data Shows 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 2Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 3Health News:Medical Groups Warn Of Climate Change's Potential Impact on Health 4Health News:New way to identify patients at risk of dysphagia after head and neck cancer treatment 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: